Loading...
•
Dec 31, 2024
Day One Q4 2024 Earnings Report
Day One Biopharmaceuticals reported its fourth quarter and full year 2024 financial results, highlighting strong OJEMDA net product revenues and corporate progress.
Key Takeaways
Day One Biopharmaceuticals achieved significant growth in Q4 2024 with OJEMDA net product revenues reaching $29.0 million, contributing to a full year total of $57.2 million. The company ended 2024 with a strong cash position of $531.7 million, indicating a solid financial foundation for future growth and mission realization.
OJEMDA net product revenues for Q4 2024 were $29.0 million, marking a 44% increase from Q3 2024.
The company ended 2024 with $531.7 million in cash, cash equivalents, and short-term investments.
OJEMDA received Exclusively Pediatric designation, reducing its Medicaid and 340B minimum rebate percentage.
Day One advanced enrollment in the global, pivotal Phase 3 FIREFLY-2 clinical trial, with full enrollment expected in the first half of 2026.
Forward Guidance
Day One Biopharmaceuticals is focused on continued growth for OJEMDA, advancing its clinical pipeline, and maintaining a strong financial position.
Positive Outlook
- Full enrollment in the global, pivotal Phase 3 FIREFLY-2 clinical trial is expected in the first half of 2026.
- The company aims for long-term, durable growth with OJEMDA as its foundation.
- Continued progress in the DAY301 clinical trial, having cleared the first dose cohort.
- Strong balance sheet provides a solid financial foundation.
- Commitment to developing and commercializing targeted therapies for life-threatening diseases across all ages.
Challenges Ahead
- Continued approval for OJEMDA's indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ significantly.
- Risks include the ability to obtain and retain regulatory approval for product candidates.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...